Geriatric Polypharmacy: A Pill for Every ill? Speaker has no relationship to disclose. Objectives. Amelie Hollier, DNP, FNP BC, FAANP President, APEA

Size: px
Start display at page:

Download "Geriatric Polypharmacy: A Pill for Every ill? Speaker has no relationship to disclose. Objectives. Amelie Hollier, DNP, FNP BC, FAANP President, APEA"

Transcription

1 Geriatric Polypharmacy: A Pill for Every ill? Amelie Hollier, DNP, FNP BC, FAANP President, APEA Speaker has no relationship to disclose. Objectives 1. Assess medications for elder appropriateness prior to prescribing 2. Develop strategies to prescribe/discontinue medications for elderly patients who are seen in primary care 3. Apply principles of safe geriatric prescribing when managing elderly patients 1

2 Fact # 1 Geriatric Patients US Life Expectancy Women: 81.0 years Men: 76.2 years Fact # 2 Geriatric Patients 2011 Elderly population increases by 30% each year from now until 2050!!! The Baby Boomers turned 65 years old in 2011! It is MORE difficult to prescribe medications in Elderly Patients Inter individual variability Polypharmacy Concomitant diseases Physiological changes associated with aging (renal, hepatic dysfunction) Multiple prescribers! 2

3 A Reasonable Approach: Always ask and answer these 3 questions before prescribing First: What is the Diagnosis? Second: What drug? Third: What dose? First Question? What s the Diagnosis? There are TWO critical considerations! First Consideration Unrecognized ADEs Adverse Drug Events In older adults, drug induced symptoms are commonly mistaken for a new disease or worsening of an existing disease Some drug induced symptoms are indistinguishable from common older adult illnesses 3

4 Second Consideration Diagnosis in the Elderly New onset of disease in an elderly patient usually affects an organ that has been weakened by a different disease process Harrison s Principles of Internal Medicine Diagnosis in Elderly Elderly Adults have atypical presentation of diseases Disease Elderly Presentation Non Elderly Presentation Anemia SOB, Angina, Fatigue Fatigue Hypothyroidism Cardiac conduction defects, cognitive changes, looks depressed Menstrual changes, constipation, changes in hair and skin UTI Confusion, anorexia Burning, frequency, urgency Take Home Point New onset of disease in an elderly patient usually affects an organ that has been weakened by a different disease process. Harrison s Principles of Internal Medicine 4

5 First Question? What s the Diagnosis? Second Question? What Drug? (or do we even need a drug?) Example: Pain in Older Adults Non pharmacologic Management Patient education Ice/Heat Massage/stretching Relaxation Biofeedback PT interventions: exercise, splints, braces 5

6 American Geriatrics Society Beers Criteria 2015 What Drug? Beers Criteria Most widely used criteria (since 1991) to assess inappropriate drug prescribing in elderly AGS Updated 2012 Beers Criteria for Potentially Inappropriate Medication (PIMS) Use in Older Adults J Am Geriatr Soc. 2015; Oct 8. doi: 10:1111/jgs : Beers Updates Lists potentially harmful drug drug interactions List of meds to avoid or have dosage reduced based on renal function List of alternatives for the Avoid List or on the potentially harmful drug disease interactions list J Am Geriatr Soc. 2015; Oct 8. doi: 10:1111/jgs

7 Beers Criteria Goal is to improve care of older adults by reducing exposure to PIMs What Makes a Drug Potentially Inappropriate for an Elderly Patient? Inappropriate Medications Anti cholinergic Side Effects Memory impairment, confusion, hallucinations, dry mouth, blurred vision, urinary retention, constipation, tachycardia, acute angle glaucoma 7

8 An Ode to an Anticholinergic Med Oh this drug, it makes me pink, Sometimes, I can t think or even blink. I can t see, I can t pee I can t spit I can t defecate (**it) Mrs. Jones is 75 years old. She is diagnosed with a UTI. Her CrCl is 30 ml/min. Which anti infective should be avoided in her for long term suppression (because of pulmonary toxicity)? 1. Sulfa drug 2. Ciprofloxacin 3. Amoxicillin 4. Nitrofurantoin J Am Geriatr Soc. 2015; Oct 8. doi: 10:1111/jgs Mrs. Jones is 75 years old. She is diagnosed with a UTI. Her CrCl is 30 ml/min. Beers Criteria recommends nitrofurantoin avoidance: For long term suppression 2012 Beers Criteria Update Expert Panel J AM Geriatr Soc. 2012;60(4): J Am Geriatr Soc. 2015; Oct 8. doi: 10:1111/jgs

9 Beers 2015: New Recommendation Beers Criteria recommends nitrofurantoin use if Cr Cl > 30 ml/min 2012 Beers Criteria recommended avoidance of nitrofurantoin if Cr Cl < 60 ml/min 2012 Beers Criteria Update Expert Panel J AM Geriatr Soc. 2012;60(4): J Am Geriatr Soc. 2015; Oct 8. doi: 10:1111/jgs What about drugs that need dose adjustment due to renal insufficiency? Excretion Age related changes in kidney function Decreases in renal mass Decreases in renal blood flow (1 2% decline/year after age 40) 9

10 Measure of Kidney Function Creatinine production is related to muscle mass Creatinine production decreases with advancing age & loss of muscle mass. This produces decreased serum Cr levels So..Normal serum Cr, but impaired renal function At what age was his serum creatinine higher? 60 years old 90 years old What Affects Creatinine Levels? What you look like What you eat Who you are 10

11 What affects serum Cr? Muscle Mass More Less More muscle mass, more serum creatinine Less muscle mass, less serum creatinine What affects serum Cr? Diet Meat Eater Vegetarian Diet Creatinine Increases but may be temporary Creatinine decreases What affects serum Cr? Age and Gender Creatinine decreases as you age (due to less muscle mass) Creatinine greater in males due to greater muscle mass 11

12 How does obesity affect serum creatinine? a. Increases Cr b. Decreases Cr c. Has no effect So. Many Factors Affect Creatinine Levels A better measure of kidney function is CrCl (ml/min) Most accurate CrCl is collected over a 24 hour period, but it s a major drag to collect!! GFR (Glomerular filtration rate = ml/min) can be used to estimate CrCl (Not Perfect, but it s pretty good!) GFR is usually estimated by Labs: egfr egfr Normal Range > 60mL/min/1.73m 2 About 38% of individuals aged 70 years or older without HTN or DM, had GFRs of < 60mL/min/1.73m 2 Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Am J Kidney Dis. 2003;41(1):1. 12

13 At what age was his GFR (or CrCl) greater? 60 years old 90 years old Excretion Decrease in GFR (50% decline between 50 and 90 years) Decrease in Creatinine Clearance Known Decreased Renal Clearance in Elderly Acetaminophen Anti arrhythmics Anti convulsants Anti depressants Anti psychotics Benzos, beta blockers, theophylline Warfarin Many, many others! 13

14 Good Rule of Thumb Be familiar with the medications you prescribe! Remember: Some drugs require renal dosing and hepatic dosing Mrs. Downs 77 year old female who relates feeling sad a lot of the time and having very low energy. She was screened for depression by her PCP using the PHQ 9. Her results indicate likely depression. She is not suicidal. How should she be managed? Assessment Many common ailments can masquerade as depression Hypo/hyperthyroidism Anemia, infection UTI Vitamin D deficiency 14

15 IF a medication is used to treat Mrs. Downs depression, which one is preferable? Which class? WHICH ONE? Where s the evidence? SSRIs SNRIs (watch CrCl for duloxetine <30 ml/min) TCAs How do you Choose an SSRI? Some Considerations: Primarily metabolized by the CYP 450 system, 2D6 enzymes Citalopram, escitalopram, sertraline have least effect on these enzymes How do you Choose an SSRI? Some Other Considerations: Safety: unsteady gait, hx of falls Ease of discontinuing treatment Safety in fragile elders Side effect profile 15

16 What abnormality is common in older patients who take SSRIs? a. Hyponatremia b. Hypokalemia c. Hyperkalemia d. Hyperglycemia Hyponatremia and SSRIs WHY? SIADH=syndrome of inappropriate secretion of antidiuretic hormone Incidence in elders: 10 40% Andreescu C, Reynolds, CF 3 rd. Late life depression: Evidence based treatment and promising new directions for research and clinical practice. Psychiatr Clin North Am 2011; 34(2): ,vii iii. Review. Hyponatremia and SSRIs What else increases risk? Older age Female gender Low body weight Diuretic, NSAID use 16

17 Hyponatremia and SSRIs How to monitor? Onset within 2 weeks Consider checking sodium level before starting or changing dose Most common symptoms: fatigue, anorexia, confusion Least common: seizures, coma, death Mrs. Downs Suppose Mrs. Downs has atrial fibrillation and takes warfarin daily? Any worries with prescribing an SSRI? What other side effects and SSRIs? Increased Bleeding risks Especially if aspirin or NSAIDs are on board 17

18 Increased Bleeding and SSRIs Mechanism??? Impaired platelet aggregation Depletion of serotonin in platelets Increased gastric acidity Increased Bleeding and SSRIs How common is this and When??? Risk is low of upper GI bleed Within 4 weeks up to many months Median time of bleeding: 25 weeks Increased Bleeding and SSRIs Reduction of Risks PPIs reduce the risk of bleeding If on warfarin, check INR more frequently Avoid concomitant use of aspirin, NSAIDs 18

19 TCAs Tricyclic Antidepressants Most extensively studied in elderly patients! Shows good efficacy! What s the problem??? Tricyclic Antidepressants Potent anticholinergic side effects!!! Sedation Orthostatic hypotension, unsteady gait, psychomotor impairment Tricyclic Antidepressants Cardiac effects: bradycardia, slowed conduction, orthostatic hypotension Monitor EKG before and during use Monitor orthostatic BP measurements Monitor pulse 19

20 Tricyclic Antidepressants Best safety profile is Secondary amines: Nortriptyline (Pamelor) Desipramine (Norpramin) Secondary Amines Here s why! Can measure levels with lab studies Use therapeutic window to guide dosing Mrs. Dash 83 year old female who has osteoarthritis in both knees. She is still mobile but complains of daily pain in her knees. She is not a surgical candidate at this time. 20

21 Mrs. Dash She self medicates with ibuprofen and she reports good pain control using 400 mg ibuprofen 2 3 times daily. Is this a Problem? Mrs. Dash She self medicates with ibuprofen and she reports good pain control using 400 mg ibuprofen 2 3 times daily. Age >75 years is a risk factor for chronic NSAID use! 2015 Beers: NSAIDs Avoid any use of indomethacin Avoid any use of ketorolac If no heart failure or renal failure and use is unavoidable, choose ibuprofen, naproxen with gastroprotection if used > 7 days J Am Geriatr Soc. 2015; Oct 8. doi: 10:1111/jgs

22 Pain Med Considerations Acetaminophen PRN or scheduled PRN first, then scheduled up to 3 grams daily Non-acetylated salicylate, capsaicin, lidocaine patch, topical NSAID, SNRI J Am Geriatr Soc. 2015; Oct 8. doi: 10:1111/jgs COX 2 NSAIDs Beers Criteria Avoid : NSAIDs Avoid in heart failure or CrCl <30 ml/min J Am Geriatr Soc. 2015; Oct 8. doi: 10:1111/jgs Gastrointestinal Risk Treat with PPI if NSAID use > 7 days 22

23 Topical NSAIDs? GI Risk? No study demonstrates greater safety with topical vs oral NSAIDs but seems unlikely There have been GI bleeds with topical NSAIDs FDA requires same standard NSAID warning on oral and topical agents???efficacy beyond 2 weeks Cost: $ /month Cardiovascular Risk COX 1 and COX 2 NSAIDs inhibit the Cyclooxygenase pathway and thus, prostaglandins COX 1 normally expressed in all tissues COX 2 usually undetectable but are present during inflammatory states 23

24 AHA Recommends for Pain CV disease or risk factors for ischemic heart disease 1. Acetaminophen 2. Aspirin 3. Tramadol 4. Opioids 5. Nonacetylated salicylates (Diflunisal) 6. NSAIDs with low COX 2 selectivity 7. NSAIDs with some COX 2 selectivity 8. COX 2 selective agents Aspirin/NSAID Interaction CV Risk: Increased risk of MI Aspirin irreversibly inhibits platelets NSAIDs reversibly bind to platelets If NSAID and Aspirin are taken together, NSAID blocks aspirin s ability to inhibit platelets Advice: Patient should take aspirin at least an hour prior to taking an NSAID! NSAID Use after MI Risk of reinfarction or death is increased if NSAID taken after recent MI Risk of reinfarction or death increased YEARS after MI CV risk after MI DOES NOT decline over time! Avoid NSAIDs indefinitely after an MI! Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Long term cardiovascular risk of NSAID use according to time passed after first time myocardial infarction: a nationwide cohort study. Circulation 2012 Sep 10 24

25 Proton Pump Inhibitors Commonly used to reduce risk of GI Bleeds One of the most widely used drug classes in 2009, 2010, 2011, 2012 (3 rd highest class in sales) Estimates that 69% are inappropriately prescribed PPI Harms 1. Infection Pneumonia/C. difficile: R/T gastric acid suppression may allow bacterial growth Care in use with patients with COPD, asthma, increased age, immunosuppression PPI Use 2. Increases ph Alters the absorption of many drugs Calcium, Fe, Vitamin D, Vitamin B12, others 25

26 PPI Harms Fracture Risk in patients > 50 years, high doses, or use > 1 year 25% increase in all fractures 47% increase in spinal fractures FDA requires fracture risk info added to labeling in OTC and Rx PPIs PPI OTC and Rx 3. Omeprazole and Na bicarb (Zegerid) Na bicarb = baking soda Allows omeprazole to be absorbed a little bit faster Each cap contains 300 mg Na Avoid in HTN, HF, or other patients in whom Na should be restricted Beers: Avoid Drug Disease or Drug Syndrome Interactions Heart Failure Syncope Dementia and Cognitive Impairment Falls and Fractures Insomnia Constipation 26

27 Beers Criteria Avoid : Heart Failure Digoxin > mg daily Higher doses associated with no additional benefit and may increase toxicity 2012 Beers Criteria Update Expert Panel J AM Geriatr Soc. 2012;60(4): Age Related Change in Pharmacokinetics As aging occurs, there is a DECREASE in total body water (10 15%) Distribution Decrease in total body water (10 15%) So, smaller distribution of water soluble drugs 27

28 Increased Drug Concentration! Serum levels increase due to decreased volume of distribution Examples: Digoxin Beers Criteria Avoid : Heart Failure Digoxin > mg daily Higher doses associated with no additional benefit and may increase toxicity 2012 Beers Criteria Update Expert Panel J AM Geriatr Soc. 2012;60(4): Mrs. Boudreaux 78 year old female who is very active and enjoys playing cards with her friends one evening per week. During the card game she has dinner and a couple of glasses of wine. She states that this has been her habit for several years but now she becomes dizzy before finishing her second glass of wine. She has had no change in weight, medications (or wine). 28

29 What is going on with Mrs. Boudreaux? a. The wine glasses are getting bigger. b. She just can t hold her liquor anymore. c. This is an age related change with EtOH metabolism. Distribution Decrease in total body water (10 15%) So, smaller distribution of water soluble (EtOH) drugs 1. Increased EtOH Concentration! Serum levels increase due to decreased volume of distribution Examples: EtOH (Mrs. Boudreaux wine) 29

30 2. Changes in EtOH Metabolism Liver mass decreases Hepatic blood flow decreases First pass metabolism decreases 3. Decreased Production of CYP 450 enzymes Can decrease up to 30% in elderly! Lots of variability (even in young, middle adults) More studies needed but, decreases in 1A2, 2C19 Decrease or no change in 3A4, 2C9 No change in 2D6 2 glasses of wine Age 48 years EtOH CYP 450: 2E1 enzymes Complete Metabolism 2E1 Enzymes Undetectable Concentrations of EtOH in blood 30

31 2 glasses of wine Age 78 years EtOH CYP 450: 2E1 enzymes Incomplete Metabolism 2E1 Enzymes Higher Concentrations of EtOH in blood What is going on with Mrs. Boudreaux? a. The wine glasses are getting bigger. b. She just can t hold her liquor anymore. c. This is an age related change with EtOH metabolism. Anti Coagulants 31

32 Speaking of warfarin. Mr. Thibodeaux takes warfarin 2 mg daily. His INR has been therapeutic. For the past 3 weeks, he has had tooth abscess with extraction and hasn t been able to eat because his dentures don t fit. He has lost 7 pounds. Considerations? Mr. Thibodeaux What important safety issue must be addressed by the NP? a. Falls precautions instituted. b. Monitor for decreased CrCl. c. Check INR. d. Check albumin level. Why? Speaking of warfarin. Warfarin is protein bound Must assume serum albumin levels decreased Mr. Thibodeaux 32

33 So if Plasma protein decreases. Patient takes 100 mg of Drug A daily. Drug A is 90% bound, that means 10 mg of drug is active. Decrease in protein of 10% IF Protein decreases by 10% (90 x.10 = 9 mg), then 19 mg free drug. Greater effect of from the drug! Drug A 10 mg Free 90 mg Bound 10% Decrease in Protein Drug A 19 mg Free 81 mg Bound What important safety issue must be addressed by the NP? a. Falls precautions instituted. b. Monitor for decreased CrCl. c. Check INR. d. Check albumin level. Why? Speaking of warfarin. More circulating warfarin! INR will be increased! Risk of bleeding increased! Mr. Thibodeaux 33

34 Take Home Point Until Mr. Thibodeaux gets his teeth back Third Question? What Dose? What dose? Most drug studies do not include geriatric patients in clinical trials 34

35 What dose? No one knows! Start low and go slow Wrap Up! Consider ADEs for ANY NEW symptom in an elder!!! Take Home Point Follow the Beers List to keep elders from unintended harm! And PIMs! 35

36 Take Home Points! Do we really need a drug? Can a safer drug be used instead? Thank you! Amelie Hollier, DNP, FNP BC, FAANP Advanced Practice Education Associates amelie@apea.com References cdc.gov Harrison s Principles of Internal medicine, Beers Criteria Update Expert Panel J AM Geriatr Soc. 2012;60(4): J Am Geriatr Soc. 2015; Oct 8. doi: 10:1111/jgs Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Am J Kidney Dis. 2013;41(1):1. Andreescu C, Reynolds, CF 3 rd. Late life depression: Evidence based treatment and promising new directions for research and clinical practice. Psychiatr Clin North Am 2011; 34(2): ,vii iii. Review. Am College of Rheumatology Guidelines for Management of Osteoarthrtis, 2012 Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Long term cardiovascular risk of NSAID use according to time passed after first time myocardial infarction: a nationwide cohort study. Circulation 2012 Sep 10 Ottawa (ON): Canadian Pharmacists Association; c2011. Benzodiazepine monograph [October 2009]. therapeutics.ca. (Accessed August 8, 2015). Potentially harmful drugs in the elderly: Beers list and more. Pharmacist's Letter/Prescriber's Letter 2014;23(9):

What s the Diagnosis?

What s the Diagnosis? Geriatric Polypharmacy: A Pill for Every Ill? Amelie Hollier, DNP, FNP-BC, FAANP President, APEA Fact # 1 Geriatric Patients US Life Expectancy Women: 81.0 years Men: 76.2 years http://www.cdc.gov/nchs/data/hus/hus13.pdf#018

More information

Geri-PARDY! (2015 Beers Criteria) Pharmacology Edition

Geri-PARDY! (2015 Beers Criteria) Pharmacology Edition Geri-PARDY! Pharmacology Edition (2015 Beers Criteria) Aurelio Muyot, MD, AGSF, FACP Assistant Professor College of Osteopathic Medicine Touro University Nevada Objectives Review the 2015 Beers Criteria

More information

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK Robert L Alesiani, PharmD, CGP Chief Pharmacotherapy Officer CareKinesis, Inc. (a Tabula Rasa Healthcare Company) 2 3 4 5 Pharmacogenomics

More information

Geriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center

Geriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center Geriatric Pharmacology Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center Silver Tsunami 2010: 40 million (13%) 2030: 72 million (20%) Baby Boomers (1946-1964)

More information

1/21/2016 UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE OBJECTIVES AGING GOALS BEERS CRITERIA

1/21/2016 UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE OBJECTIVES AGING GOALS BEERS CRITERIA UPDATE ON THE AMERICAN GERIATRICS SOCIETY 2015 BEERS CRITERIA DISCLOSURE I have no financial conflict of interest to disclose. Lacey Charbonneau, Pharm.D. PGY-1 Community Practice Resident Baptist Medical

More information

Geriatric Pharmacology

Geriatric Pharmacology Geriatric Pharmacology Janice Scheufler R.Ph.,PharmD, FASCP Clinical Pharmacist Hospice of the Western Reserve Objectives List three risk factors for adverse drug events in the elderly Discuss two physiological

More information

Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks

Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks Gretchen M. Ray, PharmD, PhC, BCACP, CDE Associate Professor UNM College of Pharmacy September 7 th, 2018 DISCLOSURES

More information

Maximizing Medication Safety UNIVERSITY OF HAWAII AUGUST 31, 2016

Maximizing Medication Safety UNIVERSITY OF HAWAII AUGUST 31, 2016 Maximizing Medication Safety UNIVERSITY OF HAWAII AUGUST 31, 2016 Adverse Drug Events (ADE s) RISK FACTORS FOR Adverse Drug Events (ADEs) 6 or more concurrent chronic conditions 12 or more doses of drugs/day

More information

Katee Kindler, PharmD, BCACP

Katee Kindler, PharmD, BCACP Speaker Introduction Katee Kindler, PharmD, BCACP Current Practice: Clinical Pharmacy Specialist Ambulatory Care, St. Vincent Indianapolis Assistant Professor of Pharmacy Practice, Manchester University,

More information

START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy

START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy Jessica DiLeo, PharmD Kate Murphy, PharmD OBJECTIVES Identify pharmacodynamic and pharmacokinetic parameters that may influence treatment

More information

IF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?

IF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE? NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this

More information

Chitra Fernando, MD March 18, 2008

Chitra Fernando, MD March 18, 2008 Chitra Fernando, MD March 18, 2008 Definition Statistics Risk factors Why older adults are more prone to ADE Manifestations Inappropriate medications for older adults What can be done to minimize adverse

More information

3/1/2018. Disclosures. Objectives. Clinical advisory board member- Daiichi Sankyo

3/1/2018. Disclosures. Objectives. Clinical advisory board member- Daiichi Sankyo Adjuvant pain medications in geriatrics Thomas B. Gregory, Pharm.D., BCPS, CPE, FASPE Clinical Pharmacy Specialist Pain Management CoxHealth Springfield, MO Disclosures Clinical advisory board member-

More information

PRESCRIBING IN THE ELDERLY. CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas

PRESCRIBING IN THE ELDERLY. CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas PRESCRIBING IN THE ELDERLY CARE HOME PHARMACY TEAM Bhavini Shah, Eleesha Pentiah & Puja Vyas LEARNING OUTCOMES Medicines Optimisation The effects of aging on health and medicines. Polypharmacy Acute Kidney

More information

Deconstructing Polypharmacy. Alan B. Douglass, M.D. Director

Deconstructing Polypharmacy. Alan B. Douglass, M.D. Director Deconstructing Polypharmacy Alan B. Douglass, M.D. Director Recognize this patient? Mrs. Brown- 82 years young Active Medical Problems Hypertension Hyperlipidemia Type 2 Diabetes Peripheral edema Osteoarthritis

More information

Medication Assessment and Quality Parameters. Norma J. Owens, PharmD, FCCP Professor of Pharmacy University of Rhode Island

Medication Assessment and Quality Parameters. Norma J. Owens, PharmD, FCCP Professor of Pharmacy University of Rhode Island Medication Assessment and Quality Parameters Norma J. Owens, PharmD, FCCP Professor of Pharmacy University of Rhode Island Financial Disclosure None of the planners, speakers, and/or members of the CME

More information

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including:

Venlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including: Medication Guide VENLAFAXINE XR (venlafaxine hydrochloride) (Extended-Release Capsules) Read the Medication Guide that comes with venlafaxine hydrochloride extended-release before you start taking it and

More information

Prevention of Medication-Related Falls Through Appropriate Medication Use. Clay Sprouse, MEd., CPhT Piedmont Technical College

Prevention of Medication-Related Falls Through Appropriate Medication Use. Clay Sprouse, MEd., CPhT Piedmont Technical College Prevention of Medication-Related Falls Through Appropriate Medication Use Clay Sprouse, MEd., CPhT Piedmont Technical College Disclosure I have no relevant financial or nonfinancial relationships to disclose

More information

Pharmaceutical Care for Geriatrics

Pharmaceutical Care for Geriatrics Continuing Professional Pharmacy Development Program Pharmaceutical Care for Geriatrics Presented by: Alla El-Awaisi; MPharm, MRPharmS, MSc Event Organizer: Dr. Nadir Kheir; PhD Disclaimer: PRESENTING

More information

Variation in drug responses & Drug-Drug Interactions

Variation in drug responses & Drug-Drug Interactions Variation in drug responses & Drug-Drug Interactions 1 Properties of an Ideal Drug Effective Safety Selective Reversible Action Predictable Freedom from drug interactions Low cost Chemically stable Sources

More information

STOPP and START criteria October 2011

STOPP and START criteria October 2011 # START and STOPP are newer criteria to identify potentially inappropriate medications in elderly, including drug drug and drug disease interactions, drugs which increase risk of falls and drugs which

More information

Medication Reviews within Care Homes. Catherine Armstrong

Medication Reviews within Care Homes. Catherine Armstrong Medication Reviews within Care Homes Catherine Armstrong What is a Medication Review? A structured, critical examination of a patient s medicines with the objective of reaching an agreement with the patient

More information

Nortriptyline vs amitriptyline in elderly

Nortriptyline vs amitriptyline in elderly Nortriptyline vs amitriptyline in elderly Amitriptyline (Elavil ) vs other antidepressants - comparative analysis amitriptyline vs divalproate, amitriptyline vs trazodone. Learn what other patients are

More information

Common Antidepressant Medications for Adults

Common Antidepressant Medications for Adults (and Citalopram (Celexa) Escitalopram (Lexapro) Fluoxetine (Prozac) Fluoxetine Weekly (Prozac Weekly) 20 in AM w/ food (10 mg in elderly or those w/ panic disorder) 20 40 40 (If age >60yo, max 20) 10 10

More information

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007

Pharmaceutical Interventions. Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Pharmaceutical Interventions Collaborative Model of Mental Health Care for Older Iowans Des Moines May 18, 2007 Outline Overview Overview of initial workup and decisions in elderly depressed individual

More information

Presentation is Being Recorded

Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

BACKGROUND Measuring renal function :

BACKGROUND Measuring renal function : A GUIDE TO USE OF COMMON PALLIATIVE CARE DRUGS IN RENAL IMPAIRMENT These guidelines bring together information and recommendations from the Palliative Care formulary (PCF5 ) BACKGROUND Measuring renal

More information

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded

9/20/2011. Integrated Care for Depression & Anxiety: Psychotropic Medication Management for PCPs. Presentation is Being Recorded Integrated Care for Depression & Anxiety Psychotropic Medication Management for Primary Care Providers Los Angeles County Department of Mental Health September 20, 2011 Presentation is Being Recorded Please

More information

Physical and Sensory Changes in the Older Adult: Considerations for Medication Management

Physical and Sensory Changes in the Older Adult: Considerations for Medication Management Physical and Sensory Changes in the Older Adult: Considerations for Medication Management Amber M. Hutchison, PharmD, BCPS Assistant Clinical Professor Auburn University Harrison School of Pharmacy Disclosure/Conflict

More information

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face.

NEW ZEALAND DATA SHEET ACUPAN TM. 3. PHARMACEUTICAL FORM White, round, biconvex, film-coated tablets (7 mm diameter) engraved APN on one face. 1. PRODUCT NAME ACUPAN 30 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains nefopam hydrochloride 30 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM

More information

Prescribing Drugs to the Elderly

Prescribing Drugs to the Elderly Answers to your questions from University of Toronto experts Prescribing Drugs to the Elderly Can drugs do more harm than good? M.A. is a 90-year-old man living at home. He has dementia and due to wandering

More information

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA

PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment

More information

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over)

Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Appendix 4B - Guidance for the use of Pharmacological Agents for the Treatment of Depression in Adults (18 years and over) Introduction / Background Treatment comes after diagnosis Diagnosis is based on

More information

SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP)

SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) 9 SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF CHRONIC NON-TERMINAL PAIN (CNTP) SUMMARY OF ARIZONA OPIOID PRESCRIBING GUIDELINES FOR THE TREATMENT OF ACUTE PAIN NONOPIOID TREATMENTS

More information

Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly

Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly Mitigating Risks While Optimizing the Benefits of Pharmacologic Agents to Manage Pain in the Elderly Mary Lynn McPherson, PharmD, MDE, MA, BCPS, CPE Professor and Executive Director, Advanced Post-Graduate

More information

SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816

SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Managing Depression in Older Adults Developed March 1, 2003 Revised September 21,

More information

POLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE

POLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE POLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE Jeannie Kim Lee, PharmD, BCPS, CGP Clinical Pharmacy Director College of Pharmacy The University of Arizona Learning Objectives: State the risks of

More information

Potential Drug Dosing Variability in Women. Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital

Potential Drug Dosing Variability in Women. Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital Potential Drug Dosing Variability in Women Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital 2 Objectives Understand the pharmacokinetic variability

More information

DEPRESCRIBING IN THE ELDERLY

DEPRESCRIBING IN THE ELDERLY DEPRESCRIBING IN THE ELDERLY G E R I A T R I C S R E F R E S H E R D A Y W E D N E S D A Y, A P R I L 5 TH, 2 0 1 7 V É R O N I Q U E F R E N C H M E R K L E Y, M D, C C F P ( C O E ) B R U Y È R E C O

More information

Meds and Falls: Keep in Step with your Meds

Meds and Falls: Keep in Step with your Meds Meds and Falls: Keep in Step with your Meds Donna Bartlett PharmD, CGP, RPh Associate Professor-Pharmacy Practice MCPHS University Clinical Pharmacist-MCPHS University- Pharmacy Outreach Program donna.bartlett@mcphs.edu

More information

There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients

There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients Marilyn N. Bulloch, PharmD, BCPS Assistant Clinical Professor

More information

TOP 5 DRUGS.. TO AVOID IN THE ELDERLY

TOP 5 DRUGS.. TO AVOID IN THE ELDERLY TOP 5 DRUGS.. TO AVOID IN THE ELDERLY Debbie Kwan, BScPhm., MSc., FCSHP Canadian Geriatrics Society, April 20, 2013 Disclosure of Potential for Conflict of Interest: Financial Disclosure: None Mar 26,

More information

Presenter. Dr. Ronald Lucchino

Presenter. Dr. Ronald Lucchino Adverse Drug Reactions in Adults with Down Syndrome Presenter Dr. Ronald Lucchino rvluc@comcast.net PURPOSE To increase staff awareness that older adults with DD may have higher levels of medication in

More information

How to Teach About Drugs and Aging

How to Teach About Drugs and Aging How to Teach About Drugs and Aging Brandon Koretz MD Assistant Clinical Professor Division of Geriatrics Challenges Prescription pad:internist::scalpel: Surgeon Artificial split between theory and practice

More information

Nursing Process Focus: Patients Receiving Levodopa (Larodopa)

Nursing Process Focus: Patients Receiving Levodopa (Larodopa) Assessment Prior to administration: Obtain complete health history including allergies, drug history and possible drug interactions. Obtain baseline evaluation of severity of Parkinson s disease to determine

More information

BLCS 1-Clinical Overview. Dr. Chris Rauscher Clinical Lead Shared Care Polypharmacy Risk Reduction Initiative

BLCS 1-Clinical Overview. Dr. Chris Rauscher Clinical Lead Shared Care Polypharmacy Risk Reduction Initiative BLCS 1-Clinical Overview Dr. Chris Rauscher Clinical Lead Shared Care Polypharmacy Risk Reduction Initiative Fraser Health Guide To Person-Centered Medication Decisions Factors to Consider When Systematically

More information

Anti-Depressant Medications

Anti-Depressant Medications Anti-Depressant Medications A Introduction: This topic may be a little bit underestimated here in Jordan, while in western countries it has more significance. The function of anti-depressants is to change

More information

Mr. Eknath Kole M.S. Pharm (NIPER Mohali)

Mr. Eknath Kole M.S. Pharm (NIPER Mohali) M.S. Pharm (NIPER Mohali) Drug Class Actions Therapeutic Uses Pharmacokinetics Adverse Effects Other Quinidine IA -Binds to open and inactivated Na+ -Decreases the slope of Phase 4 spontaneous depolarization

More information

Depression in Late Life

Depression in Late Life Depression in Late Life Robert Madan MD FRCPC Geriatric Psychiatrist Key Learnings Robert Madan MD FRCPC Key Learnings By the end of the session, participants will be able to List the symptoms of depression

More information

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist

Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Dementia Medications Acetylcholinesterase Inhibitors (AChEIs) and Glutamate (NMDA) Receptor Antagonist Medication Dosage Indication for Use Aricept (donepezil) Exelon (rivastigmine) 5mg 23mg* ODT 5mg Solution

More information

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE

Interface Prescribing Subgroup DRUGS FOR DEMENTIA: INFORMATION FOR PRIMARY CARE Cholinesterase inhibitors and Memantine are now classified as green (following specialist initiation) drugs by the Greater Manchester Medicines Management Group. Who will diagnose and decide who is suitable

More information

Fall Prevention in Hospice (A pharmacologic and nonpharmacologic approach)

Fall Prevention in Hospice (A pharmacologic and nonpharmacologic approach) Fall Prevention in Hospice (A pharmacologic and nonpharmacologic approach) Chinenye Emereole, Pharm.D. Clinical Pharmacist Hospice Pharmacy Solutions Objectives Assess and identify hospice patients who

More information

Identifying and Managing Chronic Kidney Disease: A Practical Approach

Identifying and Managing Chronic Kidney Disease: A Practical Approach Identifying and Managing Chronic Kidney Disease: A Practical Approach S. Neil Finkle, MD, FRCPC Associate Professor Division of Nephrology, Department of Medicine, Dalhousie University Program Director,

More information

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003 Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,

More information

Medication Use in Older Adults

Medication Use in Older Adults Medication Use in Older Adults F. Michael Gloth, III, MD, AGSF, FACP, CMD Clinical Professor Department of Geriatrics, Florida State University College of Medicine Associate Professor of Medicine Division

More information

Knock Out Opioid Abuse in New Jersey:

Knock Out Opioid Abuse in New Jersey: Knock Out Opioid Abuse in New Jersey: A Resource for Safer Prescribing GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN IMPROVING PRACTICE THROUGH RECOMMENDATIONS CDC s Guideline for Prescribing Opioids

More information

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.

Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed. Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of

More information

Disclosures. Outline. Epidemiology. Medication Management in the Elderly. In 2008 pts age 65 and older represented 40% of all hospitalized adults

Disclosures. Outline. Epidemiology. Medication Management in the Elderly. In 2008 pts age 65 and older represented 40% of all hospitalized adults Medication Management in the Elderly Disclosures Melissa Stevens MD Atlanta VA Medical Center Assistant Professor Emory University Department of Medicine I have no significant financial interest or other

More information

Drug Use Criteria: Oral Ketorolac/Intranasal Ketorolac (Sprix )

Drug Use Criteria: Oral Ketorolac/Intranasal Ketorolac (Sprix ) Texas Vendor Program Use Criteria: Oral Ketorolac/Intranasal Ketorolac (Sprix ) Publication History 1. Developed February 1995. 2. Revised May 2016; December 2014; March 2013; May 2011; January 2009; October

More information

(levomilnacipran) extended-release capsules

(levomilnacipran) extended-release capsules MEDICATION GUIDE FETZIMA (fet-zee-muh) (levomilnacipran) extended-release capsules Read this Medication Guide before you start taking FETZIMA and each time you get a refill. There may be new information.

More information

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT

Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND THE OLDER ADULT Objectives u At conclusion of the presentation the participant will: 1. Discuss challenges to glycemic control unique in the older population

More information

Medication Guide. Escitalopram (ES-sye-TAL-oh-pram) Tablets USP

Medication Guide. Escitalopram (ES-sye-TAL-oh-pram) Tablets USP 17.2 FDA-Approved Medication Guide Medication Guide Escitalopram (ES-sye-TAL-oh-pram) Tablets USP Read the Medication Guide that comes with escitalopram tablets before you start taking it and each time

More information

Treatment of the Medically Compromised Patient

Treatment of the Medically Compromised Patient Treatment of the Medically Compromised Patient Nashville Area Continuing Dental Education Series November 3, 2010 Harry J. Brown, MD Chief Medical Officer, Nashville Area Outline General Principles Specific

More information

Norpramin (desipramine)

Norpramin (desipramine) Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)

More information

Pamelor (nortriptyline)

Pamelor (nortriptyline) Generic name: Nortriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg capsules; 10 mg/5 ml oral solution Available in generic: Yes Drug class: Tricyclic antidepressant General Information Pamelor

More information

Drugs for Emotional and Mood Disorders Chapter 16

Drugs for Emotional and Mood Disorders Chapter 16 Drugs for Emotional and Mood Disorders Chapter 16 NCLEX-RN Review Question 1 Choices Please note Question #1 at the end of Ch 16 pg 202 & Key pg 805 answer is #4 1. Psychomotor symptoms 2. Tachycardia,

More information

Medication Guide Escitalopram Tablets (ES-sye-TAL-oh-pram)

Medication Guide Escitalopram Tablets (ES-sye-TAL-oh-pram) Medication Guide Escitalopram Tablets (ES-sye-TAL-oh-pram) Read the Medication Guide that comes with escitalopram tablets before you start taking it and each time you get a refill. There may be new information.

More information

What are you trying to achieve? Falls Prevention, Assessment and Management Strategies. Falls can be classified into four main groups:

What are you trying to achieve? Falls Prevention, Assessment and Management Strategies. Falls can be classified into four main groups: What are you trying to achieve? Falls Prevention, Assessment and Management Strategies Dr Adam Darowski Community: Falls risk assessment: Falls risk is 50% per year in 80yr population and higher in those

More information

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Guidelines MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) MANAGEMENT OF MAJOR DEPRESSIVE DISORDER (MDD) Guidelines CH Lim, B Baizury, on behalf of Development Group Clinical Practice Guidelines Management of Major Depressive Disorder A. Introduction Major depressive

More information

Family Medicine for English language students of Medical University of Lodz. Seminar 12. Elderly care. Przemysław Kardas MD PhD

Family Medicine for English language students of Medical University of Lodz. Seminar 12. Elderly care. Przemysław Kardas MD PhD Family Medicine for English language students of Medical University of Lodz Seminar 12 Elderly care Przemysław Kardas MD PhD Europe is facing demographic challenge 2014 2080 2 3 Old vs young: major differences

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care Rebecca D. Lewis, DO OOA Summer CME Oklahoma City, OK 6 August 2017 Objectives Understand the epidemiology of depression. Recognize factors to help choose antidepressants.

More information

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval

More information

If a bad thing is happening to a patient, a drug did it until proven otherwise

If a bad thing is happening to a patient, a drug did it until proven otherwise Dr Vicki s First Rule of Geriatrics Deprescribing in the Elderly Victoria Braund MD, FACP, CMD Director, Division of Geriatrics NorthShore University HealthSystem Medical Director, Brandel Health & Rehab

More information

Antidepressant Selection in Primary Care

Antidepressant Selection in Primary Care Antidepressant Selection in Primary Care R E B E C C A D. L E W I S, D O O O A S U M M E R C M E B R A N S O N, M O 1 5 A U G U S T 2 0 1 5 Objectives Understand the epidemiology of depression. Recognize

More information

Polypharmacy: What the Nurse Practitioner Should Know Audrey M. Stevenson PhD, MPH, MSN, FNP-BC Las Vegas 2017

Polypharmacy: What the Nurse Practitioner Should Know Audrey M. Stevenson PhD, MPH, MSN, FNP-BC Las Vegas 2017 Polypharmacy: What the Nurse Practitioner Should Know Audrey M. Stevenson PhD, MPH, MSN, FNP-BC Las Vegas 2017 Disclosure I have no current affiliation or financial arrangement with any grantor or commercial

More information

Part 2: Pain and Symptom Management Depression

Part 2: Pain and Symptom Management Depression Guidelines & Protocols Advisory Committee Part 2: Pain and Symptom Management Depression Effective Date: February 22, 2017 Key Recommendations Before diagnosing and treating major depressive disorder,

More information

Using the ASCP-NCOA Falls Risk Reduction Toolkit Part 1: A Companion to CDC's STEADI Toolkit

Using the ASCP-NCOA Falls Risk Reduction Toolkit Part 1: A Companion to CDC's STEADI Toolkit Using the ASCP-NCOA Falls Risk Reduction Toolkit Part 1: A Companion to CDC's STEADI Toolkit Target Audience: Pharmacists ACPE#: 0202-9999-18-056-L01-P Activity Type: Application-based Disclosures Kathleen

More information

CHAPTER 2. GERIATRICS, SELF-ASSESSMENT QUESTIONS

CHAPTER 2. GERIATRICS, SELF-ASSESSMENT QUESTIONS CHAPTER 2. GERIATRICS, SELF-ASSESSMENT QUESTIONS 1. The following is an accurate description of the aging population: A. The number of older adults will reach 17 million in 2030 B. The ratio of women to

More information

Anticoagulation Therapy in LTC

Anticoagulation Therapy in LTC Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation

More information

120 mg/day. 120 mg/day. 120 mg/day. 60 mg/day. 60 mg/day. 60 mg/day

120 mg/day. 120 mg/day. 120 mg/day. 60 mg/day. 60 mg/day. 60 mg/day 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use CYMBALTA safely and effectively. See full prescribing information for CYMBALTA. CYMBALTA (Duloxetine

More information

Polypharmacy: What the Nurse Practitioner Should Know Audrey M. Stevenson PhD, MPH, MSN, FNP-BC Nashville, TN 2017

Polypharmacy: What the Nurse Practitioner Should Know Audrey M. Stevenson PhD, MPH, MSN, FNP-BC Nashville, TN 2017 What is Polypharmacy Polypharmacy: What the Nurse Practitioner Should Know Audrey M. Stevenson PhD, MPH, MSN, FNP-BC Nashville, TN 2017 The use of multiple medications simultaneously Rx OTC Herbal Disclosure

More information

Quick Guide to Common Antidepressants-Adults

Quick Guide to Common Antidepressants-Adults Quick Guide to Common Antidepressants-Adults Medication Therapeutic Range (mg/day) Initial Suggested Serotonin Reuptake Inhibitors (SSRIs) All available as generic FLUOXETINE (Prozac) CITALOPRAM (Celexa

More information

Medications are Additive (Anticholinergic) Diane W. Healey, M.D. Center for Healthy Aging March 10, 2017

Medications are Additive (Anticholinergic) Diane W. Healey, M.D. Center for Healthy Aging March 10, 2017 Medications are Additive (Anticholinergic) Diane W. Healey, M.D. Center for Healthy Aging March 10, 2017 Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed.

More information

Partners in Care Quick Reference Cards

Partners in Care Quick Reference Cards Partners in Care Quick Reference Cards Supported by the Agency for Healthcare Research and Quality MR-1198/8-AHRQ R This project was funded by the Agency for Healthcare Research and Quality (AHRQ), formerly

More information

Doctor Discussion Guide

Doctor Discussion Guide Doctor Discussion Guide What should I tell my doctor? Talking to your doctor about depression doesn t have to be as hard as you may think. These simple tips can help you gather information and prepare

More information

Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle (Paroxetine) Capsules MIAMI and NEW YORK, January 13, 2014

Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle (Paroxetine) Capsules MIAMI and NEW YORK, January 13, 2014 Noven Enters Co-Promotion Agreement with Shionogi for Brisdelle (Paroxetine) Capsules Co-Promotion to Extend Physician Awareness of the First and Only FDA-Approved, Non-Hormonal Treatment for Moderate

More information

ANTI-ARRHYTHMICS AND WARFARIN. Dr Nithish Jayakumar

ANTI-ARRHYTHMICS AND WARFARIN. Dr Nithish Jayakumar ANTI-ARRHYTHMICS AND WARFARIN Dr Nithish Jayakumar Contents 1. Anti-arrhythmics Pacemaker and myocardial potentials Drug classes mechanisms; s/e; contra-indications Management of common arrhythmias 2.

More information

Keeping your kidneys young

Keeping your kidneys young Keeping your kidneys young Ramy M. Hanna MD FASN FACP Clinical Instructor David Geffen School of Medicine UCLA Health Department of Medicine Division of Nephrology June 25, 2018 The kidneys gets a lot

More information

GERIATRICS 101. Victoria L. Braund, MD, FACP, CMD. Director, Division of Geriatrics, NorthShore Medical Director, Symphony of Evanston

GERIATRICS 101. Victoria L. Braund, MD, FACP, CMD. Director, Division of Geriatrics, NorthShore Medical Director, Symphony of Evanston GERIATRICS 101 Victoria L. Braund, MD, FACP, CMD Director, Division of Geriatrics, NorthShore Medical Director, Symphony of Evanston LET S REVIEW Medicare Hospice Pain mgmt. Bowel business Delirium Sleep

More information

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected.

KEY MESSAGES. It is often under-recognised and 30-50% of MDD cases in primary care and medical settings are not detected. KEY MESSAGES Major depressive disorder (MDD) is a significant mental health problem that disrupts a person s mood and affects his psychosocial and occupational functioning. It is often under-recognised

More information

The Use, Misuse and Abuse of Alcohol, and Psychoactive Drugs among Older Persons

The Use, Misuse and Abuse of Alcohol, and Psychoactive Drugs among Older Persons The Use, Misuse and Abuse of Alcohol, and Psychoactive Drugs among Older Persons Alison A. Moore, MD, MPH Division of Geriatric Medicine David Geffen School of Medicine at UCLA Drinking in Older Adults:

More information

DEMENTIA AND MEDICATION

DEMENTIA AND MEDICATION DEMENTIA AND MEDICATION Dr. Siobhan Ni Bhriain, MRCP, MRCPsych. Clinical Director, Tallaght and SJH MHS, Consultant Old Age Psychiatrist, Chair, DSIDC Steering Committee. SUMMARY OF TODAY S TALK Dementia-definition,

More information

Amal AL-Anazi, BSc.(Pharm) Medication Safety Officer In Eastern Region

Amal AL-Anazi, BSc.(Pharm) Medication Safety Officer In Eastern Region Risks Of Polypharmacy Amal AL-Anazi, BSc.(Pharm) Medication Safety Officer In Eastern Region What is Polypharmacy? Polypharmacy means many drugs. In practice, polypharmacy refers to the use of more medication

More information

Acute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day

Acute Treatment: 40 mg/day (20 mg twice daily) to 60 mg/day (once daily or as 30 mg twice daily); Maintenance Treatment: 60 mg/day 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Cymbalta safely and effectively. See full prescribing information for Cymbalta. Cymbalta (duloxetine

More information

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018

GI Pharmacology. Dr. Alia Shatanawi 5/4/2018 GI Pharmacology Dr. Alia Shatanawi 5/4/2018 Drugs Used in Gastrointestinal Diseases Drugs used in Peptic Ulcer Diseases. Drugs Stimulating Gastrointestinal Motility &Laxatives. Antidiarrheal Agents. Drugs

More information

Managing Nutrition and Unintended Weight Loss

Managing Nutrition and Unintended Weight Loss Managing Nutrition and Unintended Weight Loss Kathleen Niedert, PhD, RD, CSG, FADA, LNHA 2018 Spring Conference & Exhibitor Show May 2-3, 2018 OBJECTIVES Define the three main categories and three primary

More information

Drug Interactions Year 2 Clinical Pharmacology

Drug Interactions Year 2 Clinical Pharmacology 1 Drug Interactions Year 2 Clinical Pharmacology Prof Mark McKeage Department of Pharmacology & Clinical Pharmacology 2 Objectives Explain the potential for interacting drugs to cause beneficial and harmful

More information